It's official: dramatic share price jumps in response to clinical data have become more common.
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
The pandemic provided the best and worst of times for smid-cap medtechs.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.